|Bid||38.01 x 1000|
|Ask||38.46 x 800|
|Day's range||38.39 - 39.99|
|52-week range||24.10 - 46.62|
|Beta (5Y monthly)||0.95|
|PE ratio (TTM)||13.62|
|Earnings date||21 Oct 2020 - 26 Oct 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||46.29|
Boston Scientific (BSX) aims to optimize therapy outcomes via the fourth-generation Vercise Genus DBS System's post-regulatory clearance in Europe.
Boston Scientific (BSX) gains CMS' NTAP designation for its Eluvia stent system, thus providing additional reimbursement to Medicare beneficiaries suffering from PAD.
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.